Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe.
+ 1 more risk
Adequate balance sheet and fair value.
Share Price & News
How has Summit Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UVF1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: UVF1 underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: UVF1 underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Summit Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Summit Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: UVF1 (€0.22) is trading below our estimate of fair value (€1.22)
Significantly Below Fair Value: UVF1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: UVF1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: UVF1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UVF1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UVF1 is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.5x).
How is Summit Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UVF1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: UVF1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: UVF1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: UVF1's revenue (21.1% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: UVF1's revenue (21.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UVF1 is forecast to be unprofitable in 3 years.
How has Summit Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UVF1 is currently unprofitable.
Growing Profit Margin: UVF1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UVF1 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.
Accelerating Growth: Unable to compare UVF1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UVF1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: UVF1 has a negative Return on Equity (-79.46%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Summit Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: UVF1's short term assets (£26.2M) exceed its short term liabilities (£8.0M).
Long Term Liabilities: UVF1's short term assets (£26.2M) exceed its long term liabilities (£4.5M).
Debt to Equity History and Analysis
Debt Level: UVF1 is debt free.
Reducing Debt: UVF1 has not had any debt for past 5 years.
Inventory Level: UVF1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if UVF1's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UVF1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: UVF1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.2% each year
What is Summit Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate UVF1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate UVF1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UVF1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UVF1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UVF1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Glyn Edwards (63yo)
Mr. Glyn O. Edwards, MBE serves as Chairman of Summit Therapeutics plc since December 24, 2019. Mr. Edwards has been the Chief Executive Officer of Summit Therapeutics plc since April 4, 2012. Mr. Edwards ...
CEO Compensation Analysis
Compensation vs Market: Glyn's total compensation ($USD650.28K) is above average for companies of similar size in the German market ($USD412.37K).
Compensation vs Earnings: Glyn's compensation has increased whilst the company is unprofitable.
|CEO & Chairman||7.8yrs||UK£650.28k||0.11% £96.7k|
|Co-Founder||0yrs||no data||no data|
|VP of Finance & Company Secretary||1.2yrs||no data||no data|
|Senior VP & Head of Research||0yrs||no data||no data|
|Chief Scientific Officer & Senior VP of Research and Development?||0yrs||no data||no data|
|Director of Investor Relations||4.4yrs||no data||no data|
|Senior Director of Corporate Affairs & Communications||0yrs||no data||no data|
|Vice President of Marketing||0yrs||no data||no data|
|Chief Scientific Officer of DMD||6.3yrs||no data||no data|
|Head of Clinical Development and Quantitative Sciences||2.8yrs||no data||no data|
Experienced Management: UVF1's management team is considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: UVF1 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 86.5%.
Summit Therapeutics plc's company bio, employee growth, exchange listings and data sources
- Name: Summit Therapeutics plc
- Ticker: UVF1
- Exchange: DB
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£70.593m
- Listing Market Cap: UK£84.795m
- Shares outstanding: 336.16m
- Website: https://www.summitplc.com
Number of Employees
- Summit Therapeutics plc
- 136a Eastern Avenue
- Milton Park
- OX14 4SB
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SUMM||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Oct 2004|
|UVF1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 2004|
|SMMT||NasdaqGM (Nasdaq Global Market)||SPONS ADS||US||USD||Mar 2015|
Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-571, a preclinical stage candidate to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:51|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.